Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01189 (beta-endorphin)
 21,003 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the testis of Wistar rats weighing 280-300 gms. following the administration of a single, acute intracardiac dose of methionine-enkephalin (100 microliters of 50% met-enkephalin solution), or a chronic intramuscular dose (50 microliters of 40% met-enkephalin solution). Rats were sacrificed at 15, 30 and 60 minutes following acute injection. Those on chronic treatment were injected once daily for 10 or 20 days. For the study, we utilized 105 male Wistar rats; 30 comprised the control group, and 75 comprised the study group. The following staining methods were used: 1) succinate dehydrogenase, 2) lactate dehydrogenase, 3) ATPase, 4) acid phosphatase, 5) alkaline phosphatase. We observed marked histoenzymological changes in the rat testis. Particularly noteworthy was a marked change in the energy pathways consisting of a decreased activity of aerobic pathways (decreased SDH activity), increased anaerobic activity (increased LDH activity), and consequently, decreased cellular energy stores (decreased ATPase activity). Similarly, changes were observed in other nonspecific enzymes that led to a fall in acid phosphatase activity and a rise in alkaline phosphatase activity.
 ...
PMID:[Effects of met-enkephalin on the testis. III. Histoenzymatic study]. 253 59

To correlate serial biomarkers and disease activity in carcinoma of the lung, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), adrenocorticotropic hormone (ACTH), C3-derived protein (C3DP-C), and LDH were assayed in 43 patients with small cell lung carcinoma (SCLC) and in 20 patients with non-small cell lung cancer (NSCLC) (15 with adenocarcinoma, three with squamous cell carcinoma, and two with mixed histology). Disease status after treatment was rated as one of the following: complete response, partial response, minor regression, stable disease, and progressive disease. Significant correlations between disease status and markers in SCLC were found for CEA, NSE, LDH, and ACTH. In NSCLC, only CEA and LDH showed significant correlation. Marker-marker correlations were significant in SCLC for CEA and NSE (P less than 0.05), CEA and LDH (P = 0.01), and NSE and LDH (P less than 0.01); in NSCLC none were significant. None of the markers exhibited significant correlations with specific metastatic sites. Certain biomarkers (CEA, NSE, and LDH in SCLC; CEA and LDH in NSCLC) can be used alone or in combination to monitor disease activity but appear to be no more sensitive than standard clinical investigational methods.
 ...
PMID:Multiple sequential biomarkers in monitoring patients with carcinoma of the lung. 632 8

The pro-opiomelanocortin-derived peptides beta-endorphin (beta-EP) and alpha-melanocortin (alpha-MSH) were administered to normal and dystrophic C57BL6J mice. All groups of normal and dystrophic mice which had been treated with the two peptides gained significant body weight, as did the normal and dystrophic saline-treated male controls, but the normal and dystrophic female controls did not. The plasma activity of creatine phosphokinase (CPK) was lower in normal mice and dystrophic males which had been treated with the two peptides compared to the corresponding controls. There was no significant difference between the plasma LDH activity in any of the peptide-treated and the corresponding control groups. The activity of CPK was significantly higher in the extensor digitorum longus (EDL) muscles, but not the soleus muscles, of the peptide-treated dystrophic mice compared to the corresponding controls. Administration of alpha-MSH alone or beta-EP alone had no significant effect on the body weight or plasma CPK activity of dystrophic mice compared to the controls. However the activity of CPK was significantly higher in the EDL muscles of the alpha-MSH-treated mice than in the corresponding controls. It is possible that beta-EP and alpha-MSH act synergistically on the neuromuscular system to protect the muscles from damage.
 ...
PMID:Effect of beta-endorphin and alpha-melanotropin on muscle wasting in mice. 759 3

This prospective multi-centre study was carried out in the Department of obstetrics and gynaecology of Bangabandhu Sheikh Mujib Medical University, Dhaka Medical College Hospital and Bangladesh Medical College Hospital, Shaheed Suhrawardy Medical College Hospital, Dhaka, Bangladesh, during the period of January 2008 to December 2009, to establish the raised level of serum LDH and serum CA-125 in pre-operative discrimination of benign and malignant ovarian cancer to be used as a diagnostic marker and its validity by determining sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPP). A total number of 141 consecutive suspected subjects of ovarian tumour admitted in the above mentioned hospitals and enrolled for surgical management were included in this study. Serum LDH was done in all these subjects and they were followed up from the admission upto the postoperative tissue diagnosis of live tumor in respective pathology departments for histopathological correlation. The patients who were diagnosed as malignant placed in Group I and diagnosed benign ovarian tumor placed in Group II. Serous cystadenoma and mucinous cyst adenoma were more common in benign tumors, which were 38.9% and 20.4% respectively. However, more than a half (57.1%) had serous cyst adenocarcinoma in malignant tumors. In LDH for evaluation of malignancy, true positive 16 and false positive 18, false negative 12 and true negative 95 cases. LDH and serum CA-125 level (combined, i.e. both positive) for evaluation of malignancy, true positive 14 and false positive 0, false negative 14 and true negative 113 cases. LDH/serum CA-125 level (anyone positive) for evaluation of malignancy, true positive 25 and false positive 37, false negative 3 and true negative 76 cases. The validity of LDH were sensitivity 57.1%, specificity 84.1%, accuracy 78.7%, positive predictive values 47.1% and negative predictive values 88.8% for malignancy of ovarian tumour. The validity of CA-125 were sensitivity 78.6%, specificity 82.3%, accuracy 81.6%, positive predictive values 52.4% and negative predictive values 93.9% for malignancy of ovarian tumour. The validity of LDH and serum CA-125 level (combined, i.e. both positive) for malignant ovarian tumour it was found that sensitivity 50.0%, specificity 100.0%, accuracy 90.1%, positive predictive values 100.0% and negative predictive values 89.0%.
...
PMID:Serum LDH and CA-125: Markers for Diagnosis of Ovarian Malignancy. 2600 62